Drug intelligence / Profile preview

LY-295501

Development stage: Phase 2
Lead developer: Eli Lilly
Modality: Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

LY-295501 (also known as ILX-295501) is a diarylsulfonylurea small molecule with potential antitumor activity. It was developed for the treatment of solid malignancies, including ovarian cancer, metastatic cancer, fallopian tube cancer, and primary peritoneal cavity cancer. Preclinical and clinical studies demonstrated in vivo and in vitro antitumor effects across a broad spectrum of solid tumors. The compound acts as a sulfonylurea derivative and has been investigated primarily for its cytotoxic properties against tumor cells. Development of LY-295501 has been discontinued[1][2][3][4].

Other names: N-(5-(2,3-Dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea

Targets

ClC (CLC chloride channel family)

Beyond the preview

Go deeper on LY-295501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY-295501.

Explore the full profile